Cecilia Rodrigues graduated in Pharmaceutical Sciences from the University of Lisbon in 1992 and received a PhD in Pharmacy (Biochemistry) from the same University in 1996, after PhD training at the University of Cincinnati, OH, USA. This was followed by postdoctoral work at the University of Minnesota, MN, USA. Since 2009, she is Full Professor at the Faculty of Pharmacy, University of Lisbon. Rodrigues integrates cellular and molecular technologies with multiple preclinical models of disease (metabolic, degenerative, cancer) and patient-derived models and samples for the identification of biomarkers and therapeutics that facilitate the translation from bench to bedside. She has developed bile acid derivatives as a group of promising small molecule modulators of cell death/survival, protected by patents and licensed by spin-offs that are currently in clinical trials. Rodrigues has secured independent funding from public competitive sources and/or through private investment, supervised PhD students and postdocs, and served in international editorial and grant review boards. Rodrigues is past governing board member of the European Association for the Study of the Liver.